AMPHASTAR PHARMACEUTICALS, INC. AND U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of September 15, 2023 2.00% Convertible Senior Notes due 2029Amphastar Pharmaceuticals, Inc. • September 15th, 2023 • Pharmaceutical preparations • New York
INDENTURE, dated as of September 15, 2023, between AMPHASTAR PHARMACEUTICALS, INC., a Delaware corporation, as issuer (the “Company”, as more fully set forth in Section 1.01) and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, a national banking association, as trustee (the “Trustee”, as more fully set forth in Section 1.01).
Jefferies LLC Wells Fargo Securities, LLC BofA Securities, Inc. As Representatives of the several Initial Purchasers c/o Jefferies LLC c/o J.P. Morgan Securities LLC New York, New York 10179 c/o Wells Fargo Securities, LLC New York, New York 10001 c/o...Letter Agreement • September 15th, 2023 • Amphastar Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Amphastar Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several initial purchasers named on Schedule A (the “Initial Purchasers”) $300,000,000 aggregate principal amount of its 2.00% Convertible Senior Notes due 2029 (the “Firm Securities”). In addition, the Company has granted to the Initial Purchasers an option to purchase up to an additional $45,000,000 aggregate principal amount of its 2.00% Convertible Senior Notes due 2029 (the “Option Securities”). The Firm Securities and the Option Securities are hereinafter referred to collectively as the “Securities.” Jefferies LLC, J.P. Morgan Securities LLC, Wells Fargo Securities, LLC and BofA Securities, Inc. have agreed to act as representatives of the several Initial Purchasers (in such capacity, the “Representatives”) in connection with the offering and sale of the Securities. Upon conversion, the Company will pay cash up to the aggregate principal amount of the Securities to be conver
